Vistin Pharma ASALTS:0RAM 77 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 123609.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vistin Pharma ASA's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Vistin Pharma ASA was 0.18. The lowest was 0.00. And the median was 0.01.
LTS:0RAM's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vistin Pharma ASA Debt-to-Equity Related Terms
Vistin Pharma ASA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is Vistin Pharma ASA's Debt-to-Equity too high?
Vistin Pharma ASA's current Debt-to-Equity is 0.00. Based on the distribution chart, Vistin Pharma ASA ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #999999 out of 809 companies for Debt-to-Equity. This places Vistin Pharma ASA in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.62, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Debt-to-Equity is 0.00. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.62.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Debt-to-Equity: 0.00
GF Value™: kr25.62 vs. price of kr20.70 (19.2% below fair value)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
